Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis
Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2017/8652463 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849306087390445568 |
|---|---|
| author | Gleb Makshakov Evgeniy Magonov Natalia Totolyan Vladimir Nazarov Sergey Lapin Alexandra Mazing Elena Verbitskaya Tatiana Trofimova Vladimir Krasnov Maria Shumilina Alexander Skoromets Evgeniy Evdoshenko |
| author_facet | Gleb Makshakov Evgeniy Magonov Natalia Totolyan Vladimir Nazarov Sergey Lapin Alexandra Mazing Elena Verbitskaya Tatiana Trofimova Vladimir Krasnov Maria Shumilina Alexander Skoromets Evgeniy Evdoshenko |
| author_sort | Gleb Makshakov |
| collection | DOAJ |
| description | Leptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS. |
| format | Article |
| id | doaj-art-2d04be3f6ba94a4596883c15b32f8ec4 |
| institution | Kabale University |
| issn | 2090-1852 2090-1860 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-2d04be3f6ba94a4596883c15b32f8ec42025-08-20T03:55:12ZengWileyNeurology Research International2090-18522090-18602017-01-01201710.1155/2017/86524638652463Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple SclerosisGleb Makshakov0Evgeniy Magonov1Natalia Totolyan2Vladimir Nazarov3Sergey Lapin4Alexandra Mazing5Elena Verbitskaya6Tatiana Trofimova7Vladimir Krasnov8Maria Shumilina9Alexander Skoromets10Evgeniy Evdoshenko11SBIH City Clinical Hospital No. 31, City Center of MS and Autoimmune Diseases, St. Petersburg, RussiaInstitute of Human Brain of the Russian Academy of Sciences, St. Petersburg, RussiaNeurology Department, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaCenter for Molecular Medicine, Laboratory of Autoimmune Diagnostics, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaCenter for Molecular Medicine, Laboratory of Autoimmune Diagnostics, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaCenter for Molecular Medicine, Laboratory of Autoimmune Diagnostics, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaDepartment of Clinical Pharmacology and EBM, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaInstitute of Human Brain of the Russian Academy of Sciences, St. Petersburg, RussiaNeurology Department, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaSBIH City Clinical Hospital No. 31, City Center of MS and Autoimmune Diseases, St. Petersburg, RussiaNeurology Department, FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, RussiaSBIH City Clinical Hospital No. 31, City Center of MS and Autoimmune Diseases, St. Petersburg, RussiaLeptomeningeal contrast enhancement (LMCE) on magnetic resonance imaging (MRI) is a newly recognized possible biomarker in multiple sclerosis (MS), associated with MS progression and cortical atrophy. In this study, we aimed to assess the prevalence of LMCE foci and their impact on neurodegeneration and disability. Materials. 54 patients with MS were included in the study. LMCE were detected with a 3 Tesla scanner on postcontrast fluid-attenuated inversion-recovery (FLAIR) sequence. Expanded Disability Status Scale (EDSS) score, number of relapses during 5 years from MS onset, and number of contrast-enhancing lesions on T1 weighted MRI were counted. Results. LMCE was detected in 41% (22/54) of patients. LMCE-positive patients had longer disease duration (p=0,0098) and higher EDSS score (p=0,039), but not a higher relapse rate (p=0,091). No association of LMCE with higher frequency of contrast-enhancing lesions on T1-weighted images was detected (p=0,3842). Analysis of covariates, adjusted for age, sex, and disease duration, revealed a significant effect of LMCE on the cortex volume (p=0.043, F=2.529), the total grey matter volume (p=0.043, F=2.54), and total ventricular volume (p=0.039, F=2.605). Conclusions. LMCE was shown to be an independent and significant biomarker of grey matter atrophy and disability in MS.http://dx.doi.org/10.1155/2017/8652463 |
| spellingShingle | Gleb Makshakov Evgeniy Magonov Natalia Totolyan Vladimir Nazarov Sergey Lapin Alexandra Mazing Elena Verbitskaya Tatiana Trofimova Vladimir Krasnov Maria Shumilina Alexander Skoromets Evgeniy Evdoshenko Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis Neurology Research International |
| title | Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis |
| title_full | Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis |
| title_fullStr | Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis |
| title_full_unstemmed | Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis |
| title_short | Leptomeningeal Contrast Enhancement Is Associated with Disability Progression and Grey Matter Atrophy in Multiple Sclerosis |
| title_sort | leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis |
| url | http://dx.doi.org/10.1155/2017/8652463 |
| work_keys_str_mv | AT glebmakshakov leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT evgeniymagonov leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT nataliatotolyan leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT vladimirnazarov leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT sergeylapin leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT alexandramazing leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT elenaverbitskaya leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT tatianatrofimova leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT vladimirkrasnov leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT mariashumilina leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT alexanderskoromets leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis AT evgeniyevdoshenko leptomeningealcontrastenhancementisassociatedwithdisabilityprogressionandgreymatteratrophyinmultiplesclerosis |